COMP <GO>
KRYS vs MRK // EV/EBITDA & P/E VALUATION
Krystal Biotech Inc. (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: KRYS 5
— MRK 9
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $332.29 (+2.38%) • MKT CAP: $9.61B
valuation
53.4x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KRYS VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | KRYS | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.50% | 20.70% | -4.20 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 53.4x | 15.3x | +38.10 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 1.97% | 3.42% | -1.45 | MRK | /fcf-yield <GO> |
| Operating Margin | 41.50% | 34.30% | +7.20 | KRYS | /operating-margins <GO> |
| Net Profit Margin | 52.60% | 28.10% | +24.50 | KRYS | /net-margins <GO> |
| Revenue Growth (YoY) | 33.90% | 1.30% | +32.60 | KRYS | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.19 | +20.81 | KRYS | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | KRYS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.60% | 6.60% | 0.00 | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.8 | 56.9 | -3.08 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.91 | 0.92 | -0.01 | MRK | /macro-sensitivity <GO> |
| Forward P/E Multiple | 39.4x | 18.4x | +21.00 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.61B | $361.02B | -$351.41B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | KRYS REV | MRK REV | KRYS GROSS % | MRK GROSS % | KRYS FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $65.01B | 44.0% | 74.8% | $188.9M | $12.36B |
| FY 2024 | $290.5M | $64.17B | 44.0% | 76.3% | $119.2M | $18.10B |
| FY 2023 | $50.7M | $60.12B | 44.0% | 44.0% | -$91.1M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KRYS // BETA 0.91
MRK // BETA 0.92